Enosi Life Sciences

Expanding Visionary Autoimmune & Cancer Research and Combining Multiple Scientific Solutions to Achieve a Single Goal: Improving Lives

Print
Claim My Business
Security Type
Common Stock
Categories
Healthcare & Medical
Min Investment
$500
Location
Eugene, OR
Offering Date
July 19, 2021
Expected Close Date
July 19, 2022
Target Raise
$100.00K-$1.07M
Security Price
$10
Valuation
$25,102,770
Website
enosi-life.com
Number of Employees
4
Cash
$161,839
Revenue
$0
Short Term Debt
$50,425
Cost of Goods
$0
Long Term Debt
$53,667
Net Income
$-1,068,482

Company Description

More than 30% of patients treated with life-changing therapeutics do not respond, or relapse, even with continued treatment. Enosi Life Sciences’ founders are building upon their Lasker Award-winning research to address and conquer these issues. 

Enosi’s founders are developing breakthrough biologics that will bring drugs with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. This will be the next generation of autoimmune, cancer, and acute inflammation therapies that induce disease regression and prevent relapse while reducing patient side effects. 

Enosi focuses on creating therapeutics that attack diseased cells, but not healthy cells. This results in fewer toxic effects on the patient. For instance, treatment of autoimmune disease with the current leading therapies results in an increased frequency of unusual infections, sometimes leading to death and even the occurrence of additional autoimmune disease in the same patient. In the case of cancer therapy, toxic chemotherapy is still the most common. Feldmann and Shepard aim to create new types of therapies that will be more effective and less toxic.

Perks

Investments at or above $5,000 are invited to a 30-minute Zoom to be scheduled with the Founders at the close of the campaign. This discussion will focus on an open Q&A and discussion on the science behind Enosi.

Key Deal Facts

Dr. Feldmann: Best known for inventing TNF Blockers (~$40B/year industry).
Dr. Shepard: Best known for the trastuzumab/Herceptin franchise of Genentech/Roche (~$10B/year).
Both are recipients of the Albert and Mary Lasker Award for Clinical Research .
These industry-leading experts will combine their talents, networks and experience to address the growing global health challenges of autoimmune diseases, cancer and acute inflammatory conditions.
The total autoimmune disease and TNF pathway drugs market is growing rapidly accelerating at a CAGR of nearly 10%

Use of Proceeds

 $2.5M to be raised in current offerings for us to make significant progress (timeframe 1-2y). 

A total of $5M will carry the company through its first laboratory proof of concept studies (2-3y), which could make Enosi a candidate for acquisition by a larger biotech company. 

A total of $12.5M will be needed to power Enosi to its first clinical trial.

Management Team / Advisory Board Bios

Dr. Jim Woody, Venture Capitalist, Founder, and Physician
Over 25 years of pharmaceutical research and management expertise.

Mr. Jeff Huitt, CEO
Jeff has more than 20 years' experience driving the financial function at start-ups and public companies.

Dr. Michael Shepard, CEO and Co-Founder
First FDA-approved monoclonal antibody therapy targeting breast cancer and other solid tumors...Herceptin.
Amount Raised : $140,500
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments